BioSpace News Archive

PCI Biotech, a cancer focused biopharmaceutical company announces its third quarter 2019 result.

BONE THERAPEUTICS informs its shareholders and holders of warrants and convertible bonds of the Company that an extraordinary general shareholder meeting will be held on Thursday 12 December 2019 at 10am CET, at the Company’s registered offices, rue Auguste Piccard 37, 6041 Gosselies, Belgium.

Verrica Pharmaceuticals Inc. announced that Ted White, Verrica President and CEO, will participate in a fireside chat at the Piper Jaffray 31st Annual Healthcare Conference in New York, NY on Tuesday, December 3, 2019 at 11:00 a.m. ET.

Theratechnologies Inc., a commercial-stage biopharmaceutical company, is pleased to announce that EGRIFTA SVᵀᴹ is now commercially available in the United States.

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, announced that the company was terminating its Phase 2b study of seladelpar in subjects with non-alcoholic steatohepatitis and its recently initiated Phase 2 study of seladelpar in subjects with primary sclerosing cholangitis.

NDA supported by data from two pivotal Phase 3 trials in Dravet syndrome, both of which met the primary and all key secondary endpoints, and an interim analysis from an ongoing open-label extension study

Beyond Air, Inc. announced an exclusive five-year global supply agreement for NO and NO2 calibration gas with MESA Specialty Gases & Equipment.

Oyster Point Pharma, Inc. announced that Jeffrey Nau, PhD, MMS, President and CEO, is scheduled to present at the 31st Annual Piper Jaffray Healthcare Conference on Tuesday, December 3, 2019 at 3:30 p.m. Eastern Time at the Lotte New York Palace in New York, NY.

Avadim Health, Inc. announced that it has confidentially submitted a draft registration statement on Form S-1 to the U.S. Securities and Exchange Commission relating to the proposed initial public offering of its common stock.

Tyme Technologies, Inc., an emerging biotechnology company developing cancer metabolism-based therapies, announced it will ring the Nasdaq Opening Bell on Wednesday, November 27, to honor the many stakeholders who are committed to finding a cure for patients with pancreatic cancer during Pancreatic Cancer Awareness Month.